person · Reporting owner

BONNEY MICHAEL W

Disclosed activity across 9 companies

Tapewire entity: 15604
SEC CIK: 0001219016

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	August 18, 2025	August 19, 2025
Autolus Therapeutics plcAUTL · Entity 1933	Director	June 29, 2026	July 01, 2026
BRISTOL MYERS SQUIBB COBMY · Entity 1662	Director	June 30, 2021	July 01, 2021
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813	Director	June 01, 2021	June 03, 2021
IMMUNIC, INC.IMUX · Entity 6306	Director	June 29, 2026	June 29, 2026
Kaleido Biosciences, Inc.KLDO · Entity 129745	Director	June 30, 2021	July 01, 2021
Sarepta Therapeutics, Inc.SRPT · Entity 4426	Director	February 28, 2020	February 29, 2020
Syros Pharmaceuticals, Inc.SYRS · Entity 85437	Director	June 11, 2019	June 12, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date August 18, 2025 · Filed August 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	16,804	Ending reported balance After 2025-08-18 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-08-18 · Exercise / conversion · Acquired 11,250 · Balance 28,054 F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. Row 2 · 2025-08-18 · Sale · Disposed 11,250 · Balance 16,804 F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.20 · Expires 2026-06-03	Direct	0	Reported balance After 2025-08-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-08-18 · Exercise / conversion · Disposed 11,250 · Balance 0 F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024. F3: The stock option was fully vested as of June 3, 2017.
Common StockSEC Table I · non-derivative	Indirectby Trust	4,000	Reported balance Holding disclosure · report date 2025-08-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 4,000 F2: The shares of ALNY common stock were purchased by the Michael W. Bonney Revocable Trust, of which the reporting person is trustee.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024.

F2: The shares of ALNY common stock were purchased by the Michael W. Bonney Revocable Trust, of which the reporting person is trustee.

F3: The stock option was fully vested as of June 3, 2017.

Autolus Therapeutics plc

Report date June 29, 2026 · Filed July 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	31,667	Reported balance After 2026-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29	Direct	47,500	Reported balance After 2026-06-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

F2: The RSUs vest in one installment on June 29, 2027.

F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

BRISTOL MYERS SQUIBB CO

Report date June 30, 2021 · Filed July 01, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Deferred Share UnitsSEC Table II · derivative / convertible security	Direct	9,341.7	Reported balance After 2021-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-30 · Grant · Acquired 345.331 · Balance 9,341.7 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Dianthus Therapeutics, Inc. /DE/

Report date June 01, 2021 · Filed June 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.91 · Expires 2031-05-31	Direct	18,188	Reported balance After 2021-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-01 · Grant · Acquired 18,188 · Balance 18,188 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders.

IMMUNIC, INC.

Report date June 29, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.08 · Expires 2036-05-15	Direct	100,000	Reported balance After 2026-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-29 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on May 15, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. F2: The options vest in thirty-six (36) equal installments on each monthly anniversary of May 15, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on May 15, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

F2: The options vest in thirty-six (36) equal installments on each monthly anniversary of May 15, 2026.

Kaleido Biosciences, Inc.

Report date June 30, 2021 · Filed July 01, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29	Direct	15,000	Reported balance After 2021-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2030-06-29	Direct	15,000	Reported balance After 2020-06-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-06-30 · Grant · Acquired 15,000 · Balance 15,000 F1: The original Form 4, filed on July 1, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the exercise price as $7.42 when in fact the exercise price is 7.43.

Filing footnotes · ownership attribution and instrument terms

F1: The original Form 4, filed on July 1, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the exercise price as $7.42 when in fact the exercise price is 7.43.

Sarepta Therapeutics, Inc.

Report date February 28, 2020 · Filed February 29, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,126	Reported balance After 2020-02-28 transaction · row 1 1 source row Row 1 · 2020-02-28 · Grant · Acquired 2,075 · Balance 9,126 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.47 · Expires 2030-02-28	Direct	3,685	Reported balance After 2020-02-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-28 · Grant · Acquired 3,685 · Balance 3,685

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021.

Syros Pharmaceuticals, Inc.

Report date June 11, 2019 · Filed June 12, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2029-06-10	Direct	11,000	Reported balance After 2019-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-11 · Grant · Acquired 11,000 · Balance 11,000 F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-20 transaction · row 1 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 2,209 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Common StockSEC Table I · non-derivative	IndirectTrust	Reported balance After 2019-11-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.78 · Expires 2025-04-14	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-20 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.

F2: This option was fully exercisable.

F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2020 Filed Oct 2, 2020 20:29 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	382.733	$60.29	$23,074.97	Disclosure SEC source: 0000014272-20-000261 · wf-form4_160167056399310.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,057.255 Underlying: Common Stock, $0.10 par value · 382.733 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,581	$0.00 Strike: $148.77	$0.00	Disclosure SEC source: 0001735276-20-000081 · edgardoc.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Read SEC document
June 30, 2020 Filed Jul 1, 2020 16:15 UTC	Kaleido Biosciences, Inc. KLDO · Entity 129745	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $7.42	$0.00	Disclosure SEC source: 0001209191-20-039723 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-29 Read SEC document
June 30, 2020 Filed Jul 1, 2021 16:25 UTC	Kaleido Biosciences, Inc. KLDO · Entity 129745	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $7.43	$0.00	Disclosure SEC source: 0001209191-21-044396 · doc4.xml · derivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-29 F1 · derivative.exercise_price: The original Form 4, filed on July 1, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the exercise price as $7.42 when in fact the exercise price is 7.43. Read SEC document
June 30, 2020 Filed Jul 2, 2020 20:58 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	392.432	$58.80	$23,075.00	Disclosure SEC source: 0000014272-20-000213 · wf-form4_159372347744271.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,639.199 Underlying: Common Stock, $0.10 par value · 392.432 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
June 14, 2020 Filed Jun 16, 2020 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	558	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000195 · wf-form4_159234215241704.xml · derivative · entry 5 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 558 shares Expires 2020-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · shares: On June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. F3 · derivative.exercise_date: On June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. F3 · derivative.expiration_date: On June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. Read SEC document
June 14, 2020 Filed Jun 16, 2020 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	558	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000195 · wf-form4_159234215241704.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On June 14, 2017, the reporting person was granted 1,674 restricted stock units, vesting in three equal installments beginning on June 14, 2018. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
June 13, 2020 Filed Jun 16, 2020 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	903	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000195 · wf-form4_159234215241704.xml · derivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 902 Underlying: Common Stock, $0.10 par value · 903 shares Expires 2021-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.exercise_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F1 · derivative.expiration_date: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. Read SEC document
June 13, 2020 Filed Jun 16, 2020 21:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	903	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000195 · wf-form4_159234215241704.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 13, 2018, the reporting person was granted 2,708 restricted stock units, vesting in three equal installments beginning on June 13, 2019. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:26 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $9.99	$0.00	Disclosure SEC source: 0000899243-20-015799 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
June 03, 2020 Filed Jun 5, 2020 20:40 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionRestricted Stock Units · Derivative	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000177 · wf-form4_159138960535420.xml · derivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,898 Underlying: Common Stock, $0.10 par value · 2,949 shares Expires 2022-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.exercise_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F1 · derivative.expiration_date: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. Read SEC document
June 03, 2020 Filed Jun 5, 2020 20:40 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	Exercise / conversionCommon Stock, $0.10 par value	2,949	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000177 · wf-form4_159138960535420.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 3, 2019, the reporting person was granted 8,847 restricted stock units, vesting in three equal installments beginning on June 3, 2020. F2 · price: Each restricted stock unit converts into one share of common stock upon vesting. Read SEC document
March 31, 2020 Filed Apr 2, 2020 20:50 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	413.976	$55.74	$23,075.02	Disclosure SEC source: 0000014272-20-000143 · wf-form4_158586064088540.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,215.29 Underlying: Common Stock, $0.10 par value · 413.976 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
February 28, 2020 Filed Feb 29, 2020 01:06 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	GrantStock option (right to buy) · Derivative	3,685	$0.00 Strike: $114.47	$0.00	Disclosure SEC source: 0001209191-20-014237 · doc4.xml · derivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document
February 28, 2020 Filed Feb 29, 2020 01:06 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	GrantCommon Stock	2,075	$0.00	$0.00	Disclosure SEC source: 0001209191-20-014237 · doc4.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,126 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document
February 01, 2020 Filed Feb 4, 2020 23:04 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	3,018.268	$62.95	$189,999.97	Disclosure SEC source: 0000014272-20-000060 · wf-form4_158085747868474.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,801.314 Underlying: Common Stock, $0.10 par value · 3,018.268 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
December 31, 2019 Filed Jan 3, 2020 23:48 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	126.239	$64.19	$8,103.28	Disclosure SEC source: 0000014272-20-000016 · wf-form4_157809530940270.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782.152 Underlying: Common Stock, $0.10 par value · 126.239 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document
December 04, 2019 Filed Jun 9, 2020 23:16 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	PurchaseCommon Stock, $0.10 par value	88	$58.90	$5,183.20	Disclosure SEC source: 0000014272-20-000183 · wf-form4_159174456763815.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,189 F1 · date: Due to an administrative error, this Form 4 was not timely filed. F2 · balance_after: Reflects the current total of securities beneficially owned by the reporting person, including the reported transaction. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	1,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 11 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	4,756	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 10 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	970	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 9 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 970 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	300	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 8 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	13,266	$0.00 Strike: $77.38	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 7 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $121.04	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 6 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $99.98	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 5 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-15 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $112.16	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $115.78	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · derivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-04-14 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:30 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	2,209	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001365 · form4-11222019_071120.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 21:59 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantDeferred Share Units · Derivative	655.913	$56.41	$37,000.05	Disclosure SEC source: 0000014272-19-000204 · wf-form4_157445995567267.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655.913 Underlying: Common Stock, $0.10 par value · 655.913 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2019 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	8,847	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 10 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,847 Underlying: Common Stock, $0.10 par value · 8,847 shares Expires 2022-06-03 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 3, 2020. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	1,805	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 9 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805 Underlying: Common Stock, $0.10 par value · 1,805 shares Expires 2021-06-13 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 13, 2019. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	558	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 8 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558 Underlying: Common Stock, $0.10 par value · 558 shares Expires 2020-06-14 F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018. F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on June 14, 2018. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	24,674	$0.00 Strike: $41.61	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 7 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,674 Underlying: Common Stock, $0.10 par value · 24,674 shares Expires 2028-06-13 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	19,635	$0.00 Strike: $64.73	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 6 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,635 Underlying: Common Stock, $0.10 par value · 19,635 shares Expires 2027-06-14 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	20,460	$0.00 Strike: $53.76	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 5 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,460 Underlying: Common Stock, $0.10 par value · 20,460 shares Expires 2026-06-15 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	18,700	$0.00 Strike: $59.98	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 4 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock, $0.10 par value · 18,700 shares Expires 2025-06-17 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	18,700	$0.00 Strike: $61.92	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · derivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock, $0.10 par value · 18,700 shares Expires 2025-04-14 F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, the stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	2,000	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 2,000 Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:34 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	4,069	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000216 · wf-form4a_157489406834103.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,069 F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person. F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. F3 · shares: Includes settlement of 1860 deferred share units that were paid out in connection with the Merger. Read SEC document
September 09, 2019 Filed Sep 9, 2019 18:18 UTC	Sarepta Therapeutics, Inc. SRPT · Entity 4426	PurchaseCommon Stock	2,000	$86.74	$173,480.00	Disclosure SEC source: 0001209191-19-048863 · doc4.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,051 F1 · price: The shares were purchased in multiple transactions at prices ranging from $86.50 to $86.92, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document
July 01, 2019 Filed Jul 2, 2019 20:07 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $72.01	$0.00	Disclosure SEC source: 0001735276-19-000068 · edgardoc.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document
June 15, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	375	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000726 · form4-06172019_040607.xml · derivative · entry 7 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F3 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F3 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document
June 15, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	375	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000726 · form4-06172019_040607.xml · nonDerivative · entry 3 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document
June 14, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	300	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000726 · form4-06172019_040607.xml · derivative · entry 6 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F2 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document
June 14, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	300	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000726 · form4-06172019_040607.xml · nonDerivative · entry 2 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document
June 13, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	484	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000726 · form4-06172019_040607.xml · derivative · entry 5 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 Underlying: Common Stock · 484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 485 shares on June 13, 2020 and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document
June 13, 2019 Filed Jun 17, 2019 16:00 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	484	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000726 · form4-06172019_040607.xml · nonDerivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document
June 11, 2019 Filed Jun 12, 2019 20:14 UTC	Syros Pharmaceuticals, Inc. SYRS · Entity 85437	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $5.60	$0.00	Disclosure SEC source: 0001209191-19-036358 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document
June 07, 2019 Filed Jun 11, 2019 20:59 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $13.40	$0.00	Disclosure SEC source: 0000899243-19-016406 · doc4.xml · derivative · entry 1 BONNEY MICHAEL W · CIK 0001219016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.